Benzinga | Feb 8, 2021 08:37AM EST

Predictive Oncology's Wholly Owned Subsidiary Helomics Announces The Start Of Its Drug Repurposing Project Using Its PeDAL Platform For Ovarian Cancer

MINNEAPOLIS, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), a knowledge-driven company focused on applying artificial intelligence ("AI") to personalized medicine and drug discovery, announced today that it will start an in-house drug repurposing project, focused on ovarian cancer, using its proprietary AI-driven, patient centric discovery platform -- PeDAL(tm). The project will use PeDAL to rapidly and cost-effectively profile panel of existing drugs against hundreds of patient cell lines. This process will generate data on which compounds are active against which specific patient profile(s), delivering both proof data for the PeDAL approach and valuable Intellectual Property (IP) for the company.